Vaccine against SARS-CoV-2: Challenges and considerations

Canada Communicable Disease Report

Ruchi Chaube¹ 

[1] Regulatory Operations and Enforcement Branch, Health Canada, Edmonton, AB;

关键词: vaccine;    sars-cov-2;    nucleic acid;   

DOI  :  10.14745/ccdr.v47i03a01

来源: DOAJ

【 摘 要 】

It is essential to consider challenges previously faced and addressed while developing a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the severity of the health crisis that SARS-CoV-2 has caused worldwide, and with so little known about the virus, our focus should be drawn towards approaches that can bring better development outcomes in a relatively short period of time. This commentary discusses the use of nucleic acid (deoxyribonucleic acid and ribonucleic acid) vaccines against viral infections and pandemic-like settings. The potential advantages of the nucleic acid vaccines over conventional vaccines are presented, and the nucleic acid vaccines currently in development against viral infections and the challenges these vaccines face entering clinical trial are discussed.

【 授权许可】

Unknown